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Abstract: In this review, we summarize the recent literature on dapE-
encoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) enzymes, 
with an emphasis on structure–function studies that provide insight into the 
catalytic mechanism. Crystallographic data have also provided insight into 
residues that might be involved in substrate and hence inhibitor recognition 
and binding. These data have led to the design and synthesis of several new 
DapE inhibitors, which are described along with what is known about how 
inhibitors interact with the active site of DapE enzymes, including the efficacy 
of a moderately strong DapE inhibitor. 
Keywords: DapE, Metallohydrolase, Antibiotics, Zinc, X-ray crystallography, 
Inhibitor design, Catalytic mechanism 
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Introduction 
The emergence of antibiotic-resistant bacterial infections has 
created a significant and growing medical problem throughout the 
world [1–5]. Antibiotic resistance has been recognized since the 
introduction of penicillin more than 50 years ago, when penicillin-
resistant infections caused by Staphylococcus aureus rapidly appeared 
[3, 6]. Because bacteria have been exposed to many of the currently 
available antibiotics such as β-lactams, fluoroquinolones, macrolides, 
tetracyclines, aminoglycosides, glycopeptides, and trimethoprim 
combinations for years, they have evolved resistance to these drugs 
owing to mutation of genes or the acquisition of genes that impart 
resistance from other organisms [3, 7–10]. In fact, several pathogenic 
bacteria, some of which were thought to have been eradicated, have 
made a significant resurgence owing to resistance to antibiotics [3, 6]. 
For example, tuberculosis is currently the leading cause of death in 
adults by an infectious disease worldwide, which is significant given 
that death rates due to tuberculosis had declined to near imperceptible 
levels in industrial nations [11–13]. According to the Centers for 
Disease Control and Prevention, several bacterial strains currently 
exhibit multi-drug resistance, with more than 60 % of hospital-
acquired infections in the USA caused by the so-called ESKAPE 
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species). 
Antibiotics work by interfering with a vital bacterial cell function 
at a specific cellular target by either killing the bacteria or arresting 
their multiplication [5]. This allows the patient’s immune system to 
clear the bacteria from the body. Inhibitors of cell wall biosynthesis 
(vancomycin and β-lactams, for example) have proven to be very 
potent antibiotics, providing evidence that interfering with cell wall 
synthesis has deleterious effects on bacterial cell survival. Enzymes 
that are targeted by these antibiotics tend to be present in all bacteria 
and are highly similar in structure and function, such that certain 
antibiotics kill or inhibit the growth of a broad range of bacterial 
species (i.e., broad-spectrum antibiotics) [3, 7–10]. Unfortunately, 
only two new classes of antibacterial drugs have emerged since 1962. 
According to the Infectious Diseases Society of America, at least ten 
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new systemic antibacterial drugs should enter the market by 2020, but 
most of these are derivatives of existing classes of antibiotics. Since 
every antibiotic has a finite lifetime, as resistance will ultimately occur, 
particularly if the same enzymes are repeatedly targeted, development 
of new classes of inhibitors that target previously untargeted cellular 
enzymes is essential to retain control of infectious disease [14, 15]. 
Lysine biosynthetic pathway 
From bacterial genetic information, the meso-diaminopimelate 
(m-DAP)/lysine biosynthetic pathway offers several potential 
antibacterial enzyme targets that have yet to be explored (Fig. 1) [16–
21]. One of the products of this pathway, lysine, is required in protein 
synthesis and is also used in the peptidoglycan layer of Gram-positive 
bacterial cell walls. A second product of this pathway, m-DAP, is an 
essential component of the peptidoglycan cell wall for Gram-negative 
bacteria, providing a link between poly-saccharide strands. Since 
lysine is an essential amino acid and is not synthesized by humans, it 
must be ingested. However, most bacteria, plants, and algae 
synthesize lysine and m-DAP from aspartic acid through three related 
pathways that diverge after the production of L-tetrahydrodipicolinate 
[16, 17, 22]. The presence of multiple biosynthetic pathways in 
bacteria for the synthesis of m-DAP/lysine highlights the importance of 
m-DAP/lysine for bacterial cell survival. 
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Fig. 1 Biosynthetic pathways of meso-diaminopimelic acid and lysine in 
bacteria 
The succinylase pathway is the primary biosynthetic pathway for 
m-DAP/lysine and is used by all Gram-negative and most Gram-
positive bacteria [16]. The dehydrogenase pathway forms m-DAP 
directly from L-tetrahydrodipicolinate, but this is a high-energy 
transformation and is limited to only a few Bacillus species [16]. The 
acetylase pathway is also a minor biosynthetic pathway for m-DAP 
production and is also limited to only a few Bacillus species [17]. One 
of the enzymes in the succinylase pathway, the dapE-encoded N-
succinyl-L,L-diaminopimelic acid desuccinylase (DapE), is a Zn(II)-
containing metallohydrolase. It has been shown that deletion of the 
gene encoding DapE is lethal to Helicobacter pylori and Mycobacterium 
smegmatis [23, 24]. Even in the presence of lysine-supplemented 
media, H. pylori was unable to grow, suggesting that lysine cannot be 
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synthesized by other pathways or imported. Therefore, DapE enzymes 
appear to be essential for cell growth and proliferation and are part of 
a biosynthetic pathway that is the only source of lysine in most 
bacteria. Since there are no similar biosynthetic pathways in 
mammals, DapE enzymes appear to be potential targets for inhibitors 
that may possess antimicrobial activity [16]. 
DapE enzymes contain a dinuclear Zn(II) active 
site 
DapE enzymes catalyze the hydrolysis of N-succinyl-L,L-
diaminopimelic acid (L,L-SDAP), forming L,L-diaminopimelic acid and 
succinate (Fig. 2) [22]. DapE enzymes have been purified from 
multiple sources and genes have been identified in a large number of 
pathogenic Gram-positive and Gram-negative bacteria, including all of 
the ESKAPE pathogens [23–28]. Alignment of several of the DapE 
gene sequences shows a minimum of 49 % identity [29]. Significantly, 
all of the residues that are metal binding ligands in the M28 family of 
dinuclear Zn(II)-dependent metalloproteases [30], including the 
aminopeptidase from Vibrio proteolyticus (Aeromonas proteolytica, 
AAP) and carboxypeptidase G2 from Pseudomonas sp. strain-RS-16 
(CPG2) [31, 32], are strictly conserved in all DapE enzymes. Since the 
catalytic activity of DapE enzymes requires Zn(II), and both CPG2 and 
AAP possess (μ-aquo)(μ-carboxylato)dizinc(II) active sites with one 
terminal carboxylate and one histidine residue at each metal site, a 
similar active site was proposed for DapE enzymes [22, 33–35]. 
Evidence for a dinuclear Zn(II) active site in DapE enzymes was 
obtained via zinc K-edge extended X-ray absorption fine structure 
(EXAFS) spectra of the DapE from Haemophilus influenzae in the 
presence of 1 and 2 equiv of Zn(II) (i.e., [Zn_(DapE)] and 
[ZnZn(DapE)]) [36]. Fourier transforms of the zinc EXAFS spectrum 
are dominated by a peak at approximately 2.0 Å, which was best fit 
assuming approximately five (N,O) scatterers at 1.96 and 1.98 Å for 
[Zn_(DapE)] and [ZnZn(DapE)], respectively. Inclusion of a sulfur 
atom provided poorer fits based on Debye–Waller factors. A second-
shell feature at approximately 3.34 Å appears in the [ZnZn(DapE)] 
EXAFS spectrum but is significantly diminished in the [Zn_(DapE)] 
EXAFS spectrum. These data confirmed that DapE enzymes can bind 
two Zn(II) ions that form a dinuclear site. 
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Fig. 2 Reaction catalyzed by dapE-encoded N-succinyl-L,L-diaminopimelic 
acid desuccinylase (DapE) 
Both AAP and CPG2 contain active-site histidine residues that 
function as ligands to the Zn1 and Zn2 centers. On the basis of 
sequence alignment of the DapE from H. influenzae with AAP and 
CPG2, both H67 and H349 were predicted to be Zn(II) ligands [29]. In 
an effort to clearly define the active-site residues and provide insight 
into the structural properties of each divalent metal ion in DapE 
enzymes, the H67A and H349A DapE mutant enzymes were prepared. 
The H67A DapE enzyme exhibited a decrease in catalytic efficiency 
(about 180-fold) compared with wild-type DapE toward the substrate 
L,L-SDAP. No catalytic activity was observed for H349A under the 
experimental conditions used. Electron paramagnetic resonance (EPR) 
and UV–vis data indicated that the Co(II) ion bound to H349A DapE is 
analogous to that of wild-type DapE after the addition of a single 
Co(II) ion. The addition of 1 equiv of Co(II) to H67A DapE provided 
spectra that are very different from the spectrum for the first Co(II) 
binding site of the wild-type enzyme, but are similar to the spectrum 
for the second binding site. The UV–vis and EPR data, in conjunction 
with the kinetic data, are consistent with the assignment of H67 and 
H349 as active-site metal ligands for DapE. Furthermore, these data 
suggest that H67 is a ligand in the first metal binding site, whereas 
H349 resides in the second metal binding site. 
Sequence alignment with AAP and CPG2 also suggested that the 
active-site residue in the DapE from H. influenzae, E134, likely 
functions as the general acid/base during the hydrolysis reaction 
catalyzed by DapE [22]. To elucidate the catalytic role of E134, the 
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E134A and E134D mutant DapE enzymes were prepared [37]. The 
Michaelis constant (Km) was found not to change upon substitution 
with aspartate but the kcat values changed drastically in the following 
order: glutamate (140 s−1), aspartate (0.13 s−1), and alanine (none 
detected). Examination of the pH dependence of the kinetic constants 
kcat and Km for the E134D enzyme revealed ionizations at pH 6.4, 7.4, 
and approximately 9.7. Isothermal titration calorimetry studies on 
wild-type DapE provided Kd values for the first and second Zn(II) 
binding sites of 4.4 and 13.6 μM. Isothermal titration calorimetry 
experiments on E134D DapE and E134A DapE revealed a statistically 
significant in metal Kd values of 2.9 and 1.4 times, respectively, for the 
first metal binding event. Interestingly, UV–vis and EPR spectra 
obtained on Co(II)-substituted E134D and E134A DapE did not reveal 
any significant changes, suggesting that both Co(II) ions reside in 
distorted trigonal bipyramidal coordination geometries [38]. 
Combination of these data indicates that E134 is intrinsically involved 
in the hydrolysis reaction catalyzed by DapE and likely plays the role of 
a general acid/base. 
Structural characterization of DapE enzymes 
A major limitation in developing a previously undescribed class 
of antimicrobials that target DapE enzymes was the lack of knowledge 
about their active-site structure, including potential residues involved 
in substrate binding. The X-ray crystal structure of the DapE from 
Neisseria meningitidis was reported at 1.9-Å resolution, but the DapE 
was in the apo form, providing little information about the Zn(II) 
active site [39]. Recently, the X-ray crystal structure of the DapE from 
H. influenzae was reported for both the mono and dinuclear Zn(II) 
forms at 2.0- and 2.3-Å resolution, respectively [40]. Similar to the 
DapE from N. meningitidis, the DapE from H. influenzae forms a 
homodimer where the catalytic domain consists of an α/β globular 
domain with a twisted β-sheet hydrophobic core sandwiched between 
α-helices (Fig. 3). The active-site cleft is located in the center of the 
catalytic domain above the centrally located parallel strands of the β-
sheet and is covered by loops. The location and the architecture of the 
active site are strikingly similar to those of the active sites of CPG2 
and AAP [28, 29]. 
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Fig. 3 Ribbon diagram of the X-ray crystal structure of the DapE from 
Haemophilus influenzae showing the dimer and catalytic structural domains. 
Zinc ions are shown in black (Zn1, the catalytic zinc) and gray (Zn2) 
The active site of the mononuclear Zn(II) form of DapE 
([Zn_(DapE)]) reveals that Zn1 resides in a distorted tetrahedral 
geometry coordinated by the carboxylate oxygens of D100 and E163 
as well as one nitrogen atom of H67 (Fig. 4). The remaining 
coordination site is filled by an oxygen atom provided from a water 
molecule. In the dinuclear Zn(II) form of DapE ([ZnZn(DapE)]), the 
active site contains two Zn(II) ions at an interatomic distance of 3.36 
Å, compared with 3.45 Å for AAP and 3.25 Å for CPG2 [31, 32]. Each 
of the Zn(II) ions adopts a distorted tetrahedral geometry and is 
coordinated by one imidazole group (H67 for Zn1 and H349 for Zn2) 
and one carboxylate group (E163 for Zn1 and E135 for Zn2). Both 
Zn(II) ions are bridged by an additional carboxylate group (D100) on 
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one side and water/hydroxide on the opposite side, forming a (μ-
aquo)(μ-carboxylato)dizinc(II) core with one terminal carboxylate and 
one histidine residue at each metal site. These structures confirm the 
assignment of H67 and H349 as active-site ligands, with H67 residing 
in the first metal binding site, as well as the role of Glu134. 
 
Fig. 4 Active sites of a the mononuclear Zn(II) form of DapE and b the 
dinuclear Zn(II) form of DapE from H. influenzae 
Inspection of the X-ray crystal structures of [Zn_(DapE)] and 
[ZnZn(DapE)] combined with surface analysis revealed a crescent-
shaped cavity that extends along the catalytic domain and surrounds 
the active site (Fig. 5). This well-defined, negatively charged cavity is 
shaped from the top by strand β12 and α8 and in the middle by a loop 
connecting these two elements. The bottom of the cavity is formed by 
a loop connecting strands β6 and β7, and a loop connecting β5 and α4. 
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Taking into account the linear character of the substrate, we think it is 
likely that the substrate binds in an extended conformation [41], lining 
up along the grove with the peptide bond positioned over the active-
site metals. It is conceivable that substrate binding is further stabilized 
by interaction of the substrate carboxylate groups with positively 
charged amino acid side chains. Potential candidates include K175, 
R258, and R329 (Fig. 6). In the [ZnZn(DapE)] structure, R258 and 
R329 form a charged dipole interaction with a sulfate ion, a possible 
mimic of the carboxylic group of the substrate. R329 is centrally 
positioned in a positively charged pocket that it forms together with 
R258. Interestingly, the active-site pocket of CPG2 contains an 
arginine that is conserved in DapE (R329) and has been proposed to 
bind the carboxylate group of the side chain. These data, in 
combination with the findings of reported inhibitor binding studies [35, 
36, 42, 43], indicate that DapE is an excellent target for a highly 
specific drug that should have high efficacy and low toxicity. 
 
Fig. 5 Surface rendering of the dinuclear Zn(II) form of DapE from H. 
influenzae showing the charge distribution and depicting the crescent-shaped 
active-site cavity 
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Fig. 6 Charged residues near the dinuclear active site of DapE that may play 
a role in substrate recognition and binding 
Proposed catalytic mechanism of DapE 
The X-ray structures of [Zn_DapE] and [ZnZn_DapE] provide a 
structural foundation for a proposed reaction mechanism of DapE [22, 
35, 37]. Analysis of the available structures along with the previously 
reported kinetic and spectroscopic data for DapE enzymes allowed a 
detailed mechanism of catalysis for DapE enzymes to be proposed 
(Fig. 7) [40]. On the basis of the proposed catalytic mechanism for 
AAP [44, 45], the first step in catalysis for DapE enzymes is likely 
recognition of the L,L-SDAP side chain by the crescent-shaped cavity 
adjacent to the Zn1 site. Next, the peptide carbonyl oxygen of L,L-
SDAP coordinates to Zn1 and expands its coordination number from 
four to five, activating the carbonyl for nucleophilic attack. 
Deprotonation of the metal-bound water molecule by E134 to form a 
nucleophilic hydroxide moiety is consistent with the postulated pKa of 
the zinc-bound water molecule [22]. Once the zinc-bound hydroxide 
has formed, it can attack the activated carbonyl carbon of the 
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substrate, forming an γ-1-μ-transition-state complex [36]. Solvent 
kinetic isotope effect studies yielded an inverse isotope effect that was 
explained by the attack of a zinc-bound hydroxide on the amide 
carbonyl [22]. E134 may provide a proton to the penultimate amino 
nitrogen, similar to what is observed for AAP, returning it to its ionized 
state and thus facilitating product release. Once the products have 
been released, a water molecule bridging the two metal ions is 
replaced. In the absence of the second metal ion, the catalytic 
mechanism does not likely change markedly as H349 is in a position to 
assist in orienting the substrate properly in the active site through the 
formation of a hydrogen bond with a carboxylate side chain of the 
substrate, thereby stabilizing the transition-state intermediate, 
reminiscent of proposals for the monometalated forms of AAP and the 
methionine aminopeptidase from Escherichia coli [46–48]. In the 
presence of a dinuclear site, the second metal ion likely coordinates 
either the peptide carbonyl oxygen in a bridging fashion or a 
carboxylate side chain of the substrate. 
 
Fig. 7 Proposed catalytic mechanism of a monozinc, and b dizinc DapE 
Design and synthesis of DapE inhibitors 
The design and synthesis of novel DapE inhibitors requires 
information regarding substrate specificity. Therefore, the four isomers 
of N-succinyldiaminopimelic acid (SDAP) as well as a number of 
acetylated amino acids have been examined as potential substrates. 
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DapE was not able to hydrolyze the D,D, L,D, or D,L isoforms of SDAP, 
confirming that L,L-SDAP is the only known biological substrate for 
DapE enzymes. Moreover, no hydrolytic degradation was observed for 
any acetylated amino acids tested [28, 35]; thus, the DapE active site 
has strict substrate specificity with regard to both functional groups 
and stereochemistry. These data also suggest that the carboxylate of 
the succinyl moiety forms an important interaction within the active 
site of DapE since the acetylated amino acids could not be hydrolyzed. 
Alternatively, the acetylated versions of these amino acids may 
introduce a repulsive steric interaction because of bulky alkyl groups, 
thus preventing hydrolysis. Given the lack of hydrolytic activity toward 
SDAP isoforms, a series of potential DapE inhibitors based on SDAP 
bearing different N-linked acyl side chains terminated with (1) a 
carboxyl group or (2) a lipophilic moiety were synthesized. 
Unfortunately, none of these compounds functioned as potent 
inhibitors of DapE [35, 36, 42, 43]. Finally, D,L-succinyl aminopimelate 
was examined; this differs from the natural substrate, L,L-SDAP, only 
by the absence of the amine group on the amino acid side chain. 
Interestingly, DapE could not hydrolyze this compound, implying that 
the amine provides an important interaction for substrate binding. 
The next step in inhibitor design for DapE enzymes involved 
understanding how inhibitors bind to the active site. To date, no X-ray 
structural data for a DapE enzyme in the presence of an inhibitor have 
been reported; however, zinc K-edge EXAFS spectra of [ZnZn(DapE)] 
in the presence of the competitive inhibitors 2-carboxyethylphosphonic 
acid (CEPA; Ki = 800 μM) and 5-mercaptopentanoic acid (MSPA; Ki = 6 
μM) have been reported [36]. Phosphonic acid containing compounds 
have been shown to be potent inhibitors of metallohydrolases, 
including AAP and the bovine lens leucine aminopeptidase, and have 
been used as probes of the transition state of hydrolysis reactions. The 
EXAFS data for [ZnZn(DapE)]–CEPA indicate that the average 
coordination number of each Zn(II) ion is five, and the Zn–Zn distance 
remains 3.34 Å. An increase in the M–M distance of [ZnZn(AAP)], from 
3.5 to 3.9 Å, is observed upon the addition of the transition-state 
analog inhibitor L-leucine phosphonic acid (LPA), which contains a 
ligating group similar to that in CEPA [49]. The X-ray crystal structure 
and EXAFS data for [ZnZn(AAP)]–LPA reveal that the bridging water 
molecule is displaced by LPA, resulting in an γ-1,2-μ-phosphonate 
bridge and an increase in the Zn–Zn distance of 0.4 Å. The fact that 
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the Zn–Zn distance is not altered upon CEPA binding to [ZnZn(DapE)] 
suggests an γ-1-μ-phosphonate bridge exists, similar to the binding 
mode of LPA with regard to bovine lens leucine aminopeptidase [49, 
50]. On the other hand, MSPA binding to [ZnZn(DapE)] has a marked 
effect on the zinc K-edge, suggesting that the average electronic 
environment of the dinuclear Zn(II) site has changed significantly. The 
observed shift in the position of the absorption edge to lower energy is 
indicative of a net increase in electron density at the dinuclear Zn(II) 
site, consistent with a sulfur ligand. In addition, the EXAFS data for 
[ZnZn(DapE)]–MSPA reveals a new feature at 2.3 Å that is highly 
characteristic of a direct zinc–sulfur interaction. Moreover, the M–M 
distance is lengthened from 3.34 to 3.64 Å. These data indicate that 
the thiol group of MSPA binds to one or both of the Zn(II) ions in the 
active site of DapE. 
The fact that thiol-based molecules were shown to be 
moderately strong inhibitors of DapE provided insight for examination 
of bifunctional molecules that contained, in addition to a thiol zinc 
binding group, a carboxylate moiety that could interact with the 
positively charged lysine and arginine side chains that purportedly 
reside near the active site. These studies led to the identification of 
several low micromolar inhibitors of DapE, all of which, like MSPA, 
contain a thiol functional group [42]. Thiol-containing compounds are 
typically potent monodentate inhibitors of Zn(II) metalloproteins [51]. 
One of the better inhibitors was L-penicillamine (Fig. 8), which 
exhibited an IC50 of 13.7 μM, and a measured Ki of 4.6 μM 
(competitive). DapE is stereoselective with respect to recognition of 
inhibitors, as D-penicillamine gave an IC50 of 50 μM. Given the success 
with these carboxylic acid containing thiols, L-captopril (Fig. 8), an 
angiotensin-converting enzyme inhibitor, was examined; it contains 
the requisite zinc binding group and carboxylate functionalities. L-
Captopril exhibited an IC50 of 3.3 μM and a measured Ki of 1.8 μM 
(competitive). Again, the binding is stereoselective, as D-captopril was 
an order of magnitude less potent, with an IC50 of 42.0 μM. Given the 
good potency of L-captopril, another angiotensin-converting enzyme 
inhibitor, enalapril, was screened but did not show any potency toward 
DapE. 4-Mercaptobutyric acid is also an inhibitor of DapE and exhibits 
an IC50 of 43 μM, whereas 2-mercaptobenzoic acid has a measured 
IC50 of 34 μM. For these low micromolar inhibitors, it was hypothesized 
that a negatively charged carboxylate in the molecule participates in 
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an ionic interaction with a positively charged lysine or arginine near 
the active site. 
 
Fig. 8 Structures of L-captopril and L-penicillamine 
Given that L-captopril functions as a moderately strong inhibitor 
of DapE, its efficacy was examined using a standard plate assay [42]. 
Application of L-captopril or L-penicillamine directly to plates cultured 
with E. coli showed a dose-responsive antibiotic activity for L-captopril. 
Very little inhibition was observed for 1 mg of L-captopril, but amounts 
of 5 and 20 mg demonstrated a clear positive antibiotic result. These 
data suggest that L-captopril can cross the bacterial cell membrane 
and function to inhibit bacterial cell growth. Whether DapE is the 
cellular target of L-captopril was not addressed; however, a recent 
study suggested that DapE is not the main target of L-captopril 
antimicrobial activity since L-captopril inhibited Salmonella enterica 
and E. coli in a DapE-independent manner [52]. Clearly, further 
studies are needed to verify DapE as an antimicrobial target, and such 
studies will necessitate the discovery of strong binding inhibitors that 
are specific for DapE enzymes. 
Concluding remarks 
Bacterial infections, some of which were thought to be 
eradicated, have made a significant resurgence owing to bacterial 
resistance to all known antibiotics [2–4]. Consequently, new 
compounds that combat these pathogens and target enzymes involved 
in bacterial cell wall synthesis or pathways involved in cell replication 
are in high demand [53–60]. The m-DAP/lysine biosynthetic pathway 
offers several potential antibacterial targets that have yet to be 
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explored. Although our understanding of the catalytic mechanism of 
DapE has improved markedly over the past few years, the mechanism 
has not yet been entirely delineated. For example, several substrate 
binding steps have been proposed and the roles of each metal ion 
during catalysis are still in question. Therefore, more experimental 
evidence is needed to distinguish between the competing mechanistic 
proposals for DapE. Even so, the results obtained from the studies 
described in this review have provided new insight into the structure 
and function of DapE enzymes and have led to new medicinal 
chemistry leads. Additional insight into the catalytic mechanism of 
DapE and the determinants of substrate binding will be critical for the 
rational design of selective DapE inhibitors that may function as a new 
class of antimicrobial agents. 
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DapE dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase 
EPR Electron paramagnetic resonance 
EXAFS Extended X-ray absorption fine structure 
L,L-SDAP N-Succinyl-L,L-diaminopimelic acid, LPA, L-Leucine phosphonic acid 
m-DAP meso-Diaminopimelate 
MSPA 5-Mercaptopentanoic acid 
SDAP N-Succinyldiaminopimelic acid 
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